Joint adjustment of complex or cryptic relatedness can help to greatly improve the identification of rare and common genetic variants for quantitative traits. In deep sequencing studies of admixed individuals, cryptic relatedness and population structure notoriously confound the association analyses of high-dimensional marker sets. Existing association tests are powerful for identification of functional variants in large samples with random relatedness. These tests, however, have low power to identify susceptible variants in high-dimensional SNP sets, where n (the number of observations) is smaller than or close to m (the size of the SNP set under testing).
INTRODUCTION
Deep sequencing technologies have been generating huge amounts of descriptions of rare and common DNA sequence variants. A number of sequence association tests have been developed for identifying marker sets that harbor functional genetic variants. Most of them do not jointly model cryptic relatedness, population structure and other covariates. With the growing demand of analyzing next generation sequencing data of multi-ethnic individuals, linear mixed models have become popular because of their demonstrated effectiveness in accounting for sample relatedness [3] and population stratification [4] . Within the framework of linear mixed models, famSKAT [5] , and Gemma test [6] , appeared as two powerful sequence association tests for identifying small marker sets that harbor dense functional genetic variants. These prominent tests require that the number of markers in a testing set is much smaller than the sample size. In a typical deep sequencing study, it is quite common that a small genomic region may have genotypic data of a larger number of marker loci (close to or even larger than sample size, which we call it high dimensional set or HDS), but the functional genetic variants are very sparse. In other words, high-dimensional sparse functional marker sets are common, e.g., genes, genomic regions, and causal pathways of complex phenotypes. Aforesaid tests are incompetent to identify such high-dimensional sparse-functional marker sets. Some sparse regression methods were developed to localize individual functional markers from high-dimensional marker sets, jointly modeling pedigree structure and population structure, e.g., the Lasso [7] , Ridge regression [8] , Elastic-net [9] and the USR [10] , However, these methods yield biased solutions and are ineffective to prevent discoveries of random markers and high-dimensional marker sets irrelevant to functional variants.
In this article, we first present a unified test (uFineMap) for accurately localizing causal loci. The uFineMap is a marker wise test under a scaled sparse linear mixed regression, which jointly models marker wise effect, relatedness and population stratification. It applies scaled Lp (0 < p <1) norm regularization to generate a de-biased solution. Next, we present a unified test (uHDSet) for identifying high-dimensional sparse associations in deep sequencing genomic data of related individuals. The uHDset integrates the marker wise statistics of the uFineMap to identify susceptible high-dimensional marker sets. In the uHDSet, the dependence among markers is modeled to appropriately control set-based Type I error rates. Under extensive simulations, the uFineMap outperformed the Gemma [6] and a Scaled Lasso based method [1] . The uHDSet yields higher statistical power than famSKAT and GEMMA. Applications to Framingham Heart Study also show that our method yields novel noteworthy candidate genes and pathways for follow-up studies, unlike the prominent alternative methods. Finally, caveats of the proposed methods and perspective future efforts are discussed.
METHOD
Our method focuses on constructing statistical tests, i.e., significance testing, for high-dimensional genetic data with random relatedness. Basically, we propose two significance tests: uFineMap test (single variant test) and uHDSet test (family based high dimensional set test or whole regional test). Similar as [1, 2, 11], we develop uFineMap significance test for single variants based on the scaled sparse regression [12] , which is a generalization of ordinary sparse regression. Furthermore, we build new statistics for the uHDSet test based on a combination of uFineMap statistics. The uHDSet test facilitates us to identify susceptible genes or genetic regions instead of single variants.
Notation
Let n denote the total number of subjects; m denote the number of independent variables, e.g., SNPs; and L stands for number of covariates. Assume that we have a dependent variable 1 2 ( , ,..., )
T n y y y  Y , which stands for phenotype for each subject. 
Unified scaled Lp norm regularized regression model
We assume that the phenotypes, genotypes and covariates are associated with the following linear mixed model: A general form of the unified sparse regression model with Lp (0<p<1) norm regularization is given by the following minimization problem[13]:
where the Lp (0<p<1) norm regularization is defined by
It is well studied [14] [15] [16] that Lp (0<p<1) norm regularization term gives more sparse solution than L1 norm regularization known as Lasso (least absolute shrinkage and selection operator) [7] . Based on our previous intensive simulations[13], we suggest to use L0.3 norm regularization, which is computationally efficient and yields the solution with a proper sparsity level. To keep the method flexible, we also offer different choices for the Lp (0<p<1) norm in our R code.
Besides the selection of the Lp norm, the regularization (tuning) parameter  also affects the solution of Equation (2) . The selection of optimal parameters  is, however, a difficult problem. There is no optimal rule in general. The choice depends on the purpose of estimation, for example, variable selection may demand a larger  than does the prediction. It is often helpful to optimize the objective function over a grid of points and monitor that how new predictors enter the model as  decreases. Some practical methods to choose  are the minimization of either the Bayesian information criterion (BIC) or the Akaike information criterion (AIC) as a function of  . Similarly, we can use cross-validation or stability selection [17] to select  , and hence to control the false discovery rate. However, none of the above methods can control the Type I error, especially for a region based significance test.
To avoid the puzzle of tuning parameter selection and reduce the uncertainty of sparse regression methods for model selection, we adopt the idea of scaled sparse linear regression [12] , which jointly estimates the regression coefficients and the noise level of the data. The estimated noise level is critical to correct the bias caused by the regularization term. With a correction of the bias, the de-biased estimator is applied to construct uFineMap statistics for each variable before testing for marker wise significance for each variant.
For the scaled Lp norm based sparse regression problem, we modify the problem to the following form:
In the unified scaled sparse regression, the tuning parameter  is updated in an iterative procedure. But we still need to choose an initial tuning parameter 0  to reach a solution. However, the selection of the 0  is more flexible and less sensitive to our significance test. Because the estimated noise level and the bias caused by the Lp norm regularization are both proportional to the initial 0  , they can be compensated by the procedure of constructing de-biased estimators. Furthermore, scaled Lp norm regularization can produce a robust and consistent estimation of the regression coefficients, which is critical for developing the asymptotic distribution of the de-biased estimators. For these reasons, we use scaled sparse regression.
To solve the optimization problem (3), we combine the algorithm for unified Lp norm based sparse regression [16] with that for the general scaled sparse regression [12] and propose the following algorithm.
Algorithm for Unified Scaled Lp norm sparse regression (3)
Step 1: Data centralization:
Step 2: Initialize
Step 3: Update , , ,  β α coordinately ( 1) ( )
Update regression coefficients by USR method [10] ( 1)
Step 4: If 
The de-biased version of scaled Lp norm regularized sparse regression
In HDSs (high dimensional sets), to obtain a stable and sparse solution, a regularization term is often needed. Take two widely used methods, Lasso and Ridge regression, as examples. Both of them utilize the regularization term to assure a unique and stable solution. On one hand, the regularization term can enforce most regression coefficients to shrink exactly to zero, contributing to dimension reduction; on the other hand, the bias introduced by the regularization makes the estimated non-zero regression coefficients inclined to be smaller than their true values.
To assess the asymptotic Gaussian distribution of sparse regression coefficients, a de-biased estimator is constructed. Adopting the idea of unbiased estimation [1, 18] , we develop a de-biased estimator to recover the original unbiased regression coefficients. The detailed algorithm procedure is presented below.
The Algorithm for de-biased estimator
Step 1: Set=   , where and is the estimated parameters of the scaled sparse regression (3)
Step 2: Set 
whereβ is the solution of formula (3).
Hypothesis tests and confidence intervals
Under the linear model, we assume that the true model is
where Y is the covariates adjusted phenotype; 0 β is the ground truth regression coefficients which stands for true signal. 
uFineMap tests
where M is defined by formula (4) With this property, we can directly derive the significance test for each marker. The p-value for each variable can be defined by the following:
where  is the cumulative distribution function of a standard normal distribution.
uHDSet test
Starting from the uFineMap test, we still need to control the family-wise error rate (FWER), i.e., the Type I error rates to claim the whole significant region. We intend to develop an efficient multiple testing adjustment, taking dependence into consideration, which would be more powerful than uncorrelated adjustment (e.g. the Bonferroni-Holm correction).
For uHDSet test, the null hypothesis is H0: 0 ... X Σ X , we can easily simulate its distribution and use its quantile to estimate the p-value of the uHDSet statistic S.
RESULTS

Nuclear family simulation
To explicitly evaluate the tests for common family structure while control the heritability level and sample size. We use the following linear model to generate simulation data with nuclear family structure (each family consists of two children and their parents).
where b is the effect size for causal marker.
We randomly assign 30% of variables to be rare variants (minor allele frequency < 1%), 20% of variables to be low frequency variants (1% < MAF< 5%) and the rest variables to be common variants (5% < MAF< 50%).
Data generation
The detailed procedure of performing nuclear family simulation is as follows:
Step1: Generate MAF vector independently.
Step3: For each subject i and variable j, update the genotype matrix:
Step4: Generate the vector of trait values of n subjects from model (9) for a given b.
Considering the computational burden, we set the number of variables to be 1000 throughout the simulation.
Type I error rate evaluation
To validate the statistical test, we generated ij X by the procedure in Section 3.1.1, setting n=50 and m=100. We generated the vector of trait values~(0, )
To draw a quantile-quantile (Q-Q) plot, we repeated this process 10000 times and calculated p-values at each time. The quantile of the p-value should follow U(0,1), the uniform distribution over interval (0,1). Figure 1 shows the quantile-quantile plot under the null model, with negative log10 of both expected and empirical p-values. The two dashed curves represent 95% concentration band (CB). With all the points concentrated within the 95% CB. We concluded that the observed p-values follow the uniform distribution over interval (0,1). This assures that the Type I error rate is appropriately controlled.
Similar to Figure 1, Figure 2 illustrates that the distribution of uHDSet test's p-values for the whole region agrees with the uniform distribution, indicating the validity of the adjustment of multiple testing.
In view of Figure 1 and Figure 2 , we can draw a conclusion that both of our uFineMap test and uHDSet test can control the Type I error rate.
Statistical power analysis
We simulated the design matrix by the same procedure as in Section 3.1.1. We set the nominal significance level at 0.05 and generated the vector of trait values from model (9), for various values of heritability H. We define the heritability H to be the ratio of variance between true signal and the whole output, which can be explicitly expressed as:
Xβ Xβ
Similar to the previous design, we simulated the measure matrix n p  X generated by Gaussian noise with n=50 and m=100. We assigned the ground truth to be 0 1 {1,3,5,7,9,11} ( ) 0
i.e., the true signal to be recovered. We set two of the causal variants to be rare variants and the other four as common variants.
We increased the signal level H from 0 to 1 and calculated its power at each step based on formula (6) . Because of the limitation of computational time, we repeated the procedure 2000 times for each given H.
The statistical power for the uFineMap test is defined by the following. To evaluate our method, we compare our uFineMap test with another high-dimensional inference method (e.g., Scaled Lasso [1] ).
For uHDSet test method, we additionally consider the comparison with a popular regional based association test, famSKAT [22] , and the results are shown in Figure 3 and Figure 4 .
In Figure 3 , our uFineMap test performs the best and uniformly better than Scaled Lasso, Gemma and single marker test. Figure 3 indicates that our uFineMap test has a higher power to identify both common and rare causal variants. Similar as Figure 3 and Figure4, Figure 5 and Figure 6 indicate that the statistical power of all regional tests will increase with the growth of sample size and heritability, which is consistent with our expectation. In addition, at the lower sample size area, our uHDSet test performs much better than famSKAT and Gemma. With the increase of the sample size, the powers of the three methods converge to the same value.
In conclusion, our proposed method has higher power under lower sample size and lower signal level or heritability, while it performs equally well for large sample size and high signal level.
Complex family simulation
To compare different methods fairly, we used the software SeqSIMLA2. SeqSIMLA2 can simulate sequence data in families under quantitative disease models.
Using SeqSIMLA2, we generate quantitative traits for 8 large families (the family tree for each family is shown in Figure 9 ) with 1000 SNPs in total, and randomly assign 50 causal variants (25 common, 25 rare) to generate the continuous phenotype.
We proposed two simulation setting for markers effects. We assign all causal markers to be positively related to the trait value for the same causal direction setting. For the different causal direction setting, half of the causal markers are randomly given a negative relationship with the trait value. To make the presentation concise, we only show the result of regional tests, the result of marker wise tests can be found in the appendix. We can draw the conclusion that all three methods are robust with respect to causal variants direction. But our uHDSet test is almost uniformly more powerful than Gemma and famSKAT under SeqSIMLA simulation data.
Analysis of sequence data from Framingham Heart Study
To demonstrate the effectiveness of our methods for real genetic variants detection, we applied them to the analysis of sequence data of Framingham Heart Study. This dataset contains both GWAS and next generation sequencing (NGS) data from 4229 subjects with HipBMD data. We used the FISH [23] method for genotype imputation and selected HipBMD as the phenotype data. After quality control, we obtained 3322 individuals with 6,500,475 SNPs in total. We apply two kinds of data analysis strategies: whole genome analysis and pathway based analysis.
Whole genome analysis
We separate each chromosome into several genetic windows and then apply our uFineMap and uHDSet tests in each window. We set the window size to be 100kb base pairs. After the separation the whole genome is separated by a total number of 16514 sets of markers. The phenotype is adjusted by the covariates and the top 10 principle components of the genotype before the application of the proposed method. Following the same process as in the simulation studies, we obtain the results and draw the Manhattan plots shown by Figure 9 and Figure 10 .
By combining the overlapped region of Figure 9 and Figure 10 , the uFineMap test and uHDSet test report 68 regions of highest susceptibility that exceed a p-value threshold of 0.001. The reported p-value is based on the whole regional test. According to GeneCards websites, there are 11 genes (Table 1) within the selected regions are associated with BMD or osteoporosis disease, which further confirms our findings. 
Pathway analysis
To further illustrate the benefit of the uHDSet test. We totally collect 880 pathways from KEGG, REACTOME and BIOCARTA pathway analysis databases. We first extract genes belonging to each pathway, then select the corresponding SNPs. The selected SNPs of a specific pathway are combined to form the design matrix for association tests. We listed 6 most significant pathways that pass p-value cut-off 10 -3 at Table 2 . The three P38/MAPK pathways were previously found to play a critical role by other publications [24, 25] . Endogenous Sterols pathway is also related with BMD reported by another study [26] . Chemokines pathway is important regulator in development, homeostasis and pathophysiological processes associated with osteoporosis [27] . Each p-value in Table 2 is generated based on a whole pathway-based region. Consequently, our uHDSet method is more powerful than famSKAT in identifying significant pathways which contain relative large number of genetic markers.
CONCLUSION
Many existing association tests with adjustment of family structure have been established on the LDSs (low dimensional sets). To overcome the limitations of these tests, we propose new scaled linear mixed sparse regression association tests for assessing the significance of the HDSs. The proposed tests are designed to address the challenge of variants detection under complex pedigree structures and provide an explicit way to appropriately control the Type I error rate in both, single marker level and SNPs set level. By doing this, we overcome the limitations of several existing sequence association (i.e., famSKAT and Gemma) and sparse regression methods (i.e., Scaled Lasso).
The promising results indicate that the uFineMap test can efficiently pinpoint single suspected variants, and the uHDSet test yields a considerably high statistical power gain in comparison to other competing methods, especially for high dimensional data with cryptic relatedness. The uFineMap test can pinpoint single susceptible variants with higher resolutions, even for rare functional variants. In addition, our methods also maintain substantial power for detecting susceptibility variants in low dimensional data or large samples. Last but not least, our methods can identify both rare and common variants efficiently.
Like most existing methods, the newly proposed method has limitations. One limitation is that we assume a linear mixed relationship between phenotype and genotype, which might not be true in the real world. Therefore, nonlinear regression models with adjustment of relatedness and population stratification may be more suitable. In addition, the computational time of required by for the unbiased estimator is 2 3 O( ) n m , which is much longer than simply solving the sparse regression model, particularly for extremely large data.
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